Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction
NCT: NCT06955936 · RECRUITING
Brief Summary
Cardiogenic shock is the most severe manifestation of acute heart failure and remains the leading cause of death in patients hospitalised with acute myocardial infarction. Cardiogenic shock is a well-known and potent trigger of the immune response, ischemia/reperfusion organ damage, hemolysis and release of free hemoglobin. The activation of immune cells leads to the release of cytokines and inflammatory mediators such as IL-6, IL-8, activated complement and others. As a result of myocardial ischaemia and reperfusion injury, a multiorgan dysfunction syndrome may develop. The Efferon CT hemoadsorption device effectively removes cytokines and other pro-inflammatory molecules (≤55 kDa). This study evaluates whether this blood-filtering therapy can prevent organ failure in acute myocardial infarction patients with cardiogenic shock by eliminating inflammation-inducing mediators.
Frequently Asked Questions
What is Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction?
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction is a clinical trial registered under NCT06955936. Current status: RECRUITING.
What is the status of NCT06955936?
The current status of NCT06955936 (Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction) is: RECRUITING.
When did Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction start?
Efferon CT Hemoadsorption for Cardiogenic Shock in Acute Myocardial Infarction started on 2025-04-29.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.